Lilly’s lepodisiran shows 94% reduction in lipoprotein(a), offering hope for cardiovascular risk management
Lilly’s lepodisiran slashed lipoprotein(a) by 94% in a Phase 2 trial. See how this breakthrough could change cardiovascular disease treatment. Read More
Glenmark Pharmaceuticals expands cardiometabolic portfolio with new Empagliflozin drug launch
Glenmark Pharmaceuticals Ltd. has introduced Empagliflozin, a widely recognized SGLT2 inhibitor, in India under the brand name Glempa. Along with this, the company has launched ... Read More
Gene Hackman’s death confirmed as cardiovascular disease and Alzheimer’s, wife died from hantavirus
The cause of death of Academy Award-winning actor Gene Hackman and his wife, Betsy Arakawa, has been officially confirmed by medical investigators, shedding light on ... Read More
How a balanced diet and regular exercise can help prevent strokes
Adopting a healthy lifestyle remains the most effective strategy to prevent strokes and heart attacks. Scientific research consistently supports the notion that a balanced diet ... Read More
Sanofi strengthens cardiovascular portfolio with Aficamten rights in Greater China
Cytokinetics, Incorporated (NASDAQ: CYTK) saw its shares climb by 4.8% after announcing a landmark agreement with Sanofi (NASDAQ: SNY). The deal grants Sanofi exclusive rights ... Read More
Johnson & Johnson to acquire V-Wave Ltd. in $1.1bn deal to enhance heart failure treatment
Johnson & Johnson (NYSE: JNJ) has made headlines with its decision to acquire V-Wave Ltd., a private company renowned for its cutting-edge treatments for heart ... Read More
Reflow Medical launches DEEPER CORONARY study in coronary in-stent restenosis
Reflow Medical, Inc. ignites a medical revolution with the first patient enrollments in a pilot study named "DEEPER CORONARY." This pivotal research, set to radically ... Read More
Philips surpasses 1500 cath lab installations in India, enhancing cardiac care
Royal Philips, a global leader in health technology, announced a significant milestone at India Live 2024 in New Delhi: the completion of over 1500 Cath ... Read More
GE HealthCare launches Allia IGS Pulse after FDA 510(k) clearance
GE HealthCare (Nasdaq: GEHC) has stepped into a new era of cardiovascular imaging by announcing the FDA 510(k) clearance of Allia IGS Pulse, a significant ... Read More
Roche, Alnylam’s Zilebesiran meets primary endpoint in KARDIA-1 trial
Breaking news in the world of hypertension treatment, Roche and Alnylam Pharmaceuticals have announced the success of their Phase 2 study KARDIA-1. The investigational RNAi ... Read More